CREBBP and diffuse large B-cell lymphoma: To identify resistant models, we evaluated 10 DLBCL cell lines with different cell-of-origin and CREBBP mutation statuses for their response to RGFP966 [19], a highly selective HDAC3 inhibitor (Fig. 1A, B; see Supplementary Data 1 for details of CREBBP mutation analysis).